Key Takeaway: Voyager Therapeutics reported its second quarter 2023 financial and operating results, highlighting the introduction of a new vectorized anti-Aβ antibody gene therapy initiative aimed at Alzheimer's disease. The company also executed a license agreement with Sangamo for a treatment targeting prion disease. Additionally, they presented promising preclinical results demonstrating improved brain transduction from IV administration.
Price reaction · baseline $9 (2023-08-02 close) · hit pre-market · 2 other VYGR headline(s) in the window, move may be shared
day 0 close · peak
+3.4%
Market Sentiment Analysis
POSITIVE FACTORS
Introduction of a new gene therapy research initiative for Alzheimer's disease.
Execution of a license agreement with Sangamo for prion disease treatment.
Presentation of validating preclinical results showing increased brain transduction.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+14%
120-day peak, hindsight
Typical move
3%
average across 2 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
VP4896
Phase 3 · Alzheimer's Disease
Full Press Release Details
– Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio – – Executed license agreement with Sangamo for prion disease treatment – – Presented validating preclinical results including increased brain transduction of IV-administered
Frequently Asked Questions
What new initiative did Voyager Therapeutics introduce?
They introduced a new vectorized anti-Aβ antibody gene therapy research initiative.
What agreement did Voyager execute with Sangamo?
They executed a license agreement for a treatment targeting prion disease.
What results did Voyager present in their report?
They presented preclinical results showing increased brain transduction from IV administration.